Poster Abstract Session:
60. HIV: Antiretroviral Therapy
Thursday, October 4, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, HIV-STD-TB, Pediatric ID

Integrase Inhibitor-Based HAART is Associated with Greater BMI Gains in Blacks, Hispanics and Women
Roger Bedimo, MD; Beverley Adams-Huet, MS; Barbara S. Taylor, MD, MS; Jordan Lake, MD, MSc; Amneris Luque, MD
GS-CA2: A Novel, Potent and Selective First-In-Class Inhibitor of HIV‑1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long‑Acting Potential in Humans
Jim Zheng, PhD; Stephen R. Yant, PhD; Shekeba Ahmadyar, BS; Tiffany Y. Chan, BS; Anna Chiu, PhD; Tomas Cihlar, PhD; John O. Link, PhD; Bing Lu, BS; Judy Mwangi, MS; William Rowe, PhD; Scott D. Schroeder, BS; George J. Stepan, BS; Kelly Wei Wang, MS; Raju Subramanian, PhD; Winston C. Tse, PhD
Investigating the Mechanism of a Unique Human Immunodeficiency Virus-1 (HIV-1) Entry Inhibitor, MF275
Connie Zhao, BS; Amy Princiotto, BS; Mark Farrell, PhD; Amos B. Smith III, PhD; Navid Madani, PhD; Joseph Sodroski, MD
  • IDWeek poster.pdf (1.8 MB)
  • 541
    Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging
    Christoph D. Spinner, MD; Bruce Rashbaum, MD; Cheryl Mcdonald, MD; Cristina Mussini, MD; Donghan Luo, PhD; John Jezorwski, MS; Kimberley Brown, PharmD, AAHIVE; Eric Y. Wong, PhD
    An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
    Melanie Thompson, MD; Chloe Orkin, MBBCh; Jean-Michel Molina, MD; Jose Gatell, MD, PhD; Paul Sax, MD; Pedro Cahn, MD, PhD; Kathleen Squires, MD; Yan Zhou, PhD; Xia Xu, PhD; Anthony Rodgers, MS; Sushma Kumar, PhD; Hedy Teppler, MD; Elizabeth Martin, DO, MPH; George Hanna, MD; Carey Hwang, MD, PhD
    Pharmacokinetic profile of ibalizumab from a Phase 3 trial
    Princy N. Kumar, MD, FIDSA; Steven Weinheimer, PhD; Zvi Cohen, PhD; Christian Marsolais, PhD; Kuei-Ling Kuo, PhD; Stanley Lewis, MD
    No difference in MK-8591 and doravirine pharmacokinetics after co-administration
    Randolph Matthews, MD, PhD; Deanne Rudd, PhD; Kerry Fillgrove, PhD; Sabrina Fox-Bosetti, MPH; Vanessa Levine, MS; Sandra Zhang, PhD; Charles Tomek, MD; Aubrey Stoch, MD; Marian Iwamoto, MD, PhD
    Results of Patient-Reported Outcome Data from the Phase III BRIGHTE Study of Fostemsavir
    Clare Proudfoot, PhD; Peter Ackerman, MD; Cyril Llamoso, MD; David Cella, PhD; Andrew Clark, MD; Miranda Murray, PhD
    Antiretroviral Therapy Regimen Characteristics within an Urban, Safety-Net Clinic in the United States
    Kellie Hawkins, MD, MPH; Margaret Mclees, MD; Sarah Rowan, MD; Robert Beum, CCP; William J. Burman, MD; Edward Gardner, MD
  • IDSA 2018 poster 548.pdf (631.7 kB)
  • 549
    Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
    Amanda Gibson, PharmD; Adam Spivak, MD; Angela Presson, PhD; Christine Jamjian, PharmD, AAHIVP
    Adherence and Persistency with Modern Single vs Multi-Tablet Antiretroviral (ARV) Regimens in 1st treatment of HIV in Clinical Practice.
    Anthony Mills, MD; Julie Priest, MSPH; Alexander Musallam, MPH; Keri Althoff, PhD; Joseph Eron, MD; Greg Huhn, MD; Dushyantha Jayaweera, MD, MRCOG, FACP; Karam Mounzer, MD; Graeme Moyle, MD; Joe Mrus, MD, MSc; Moti Rampogal, MD; Steven Santiago, MD; Paul Sax, MD; Gene Voskuhl, MD; Alan Oglesby, MPH; Richard Elion, MD
    MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel
    Wendy Ankrom, PhD; Daniel Jonathan, PharmD; Deanne Rudd, PhD; Sandra Zhang, PhD; Kerry Fillgrove, PhD; Kezia Gravesande, PharmD; Randolph Matthews, MD, PhD; Darin Brimhall, DO, FACP; Aubrey Stoch, MD; Marian Iwamoto, MD, PhD
    Evaluation of Relationships between UGT1A1 Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics among HIV-infected subjects in the LATTE-2 Study
    Zhengyu Xue, MS; Karen S. King, BSc; Susan L. Ford, PharmD; Yu Lou, MS; Kalpana K. Bakshi, MS; David A. Margolis, MD, MPH; Arlene R Hughes, PhD; William R. Spreen, PharmD; Parul Patel, PharmD
    Does Protease Inhibitor (PI) Monotherapy Select Primary PI Resistance?
    Christopher Saling, MD; Liana Atallah, MPH; Tyler Haddad, BS, BA; Brooke Learned, BS; Jihad Slim, MD
  • PIposter3.pdf (984.7 kB)
  • 555
    Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States
    Philip Lackey, MD; Kathy Schulman, MA; Jennifer Fusco, BS; Jean Marie Arduino, ScD, MS; Girish Prajapati, M.B.B.S., MPH; Gregory Fusco, MD, MPH
  • RALQD_IDWeek_FINAL.pdf (392.4 kB)
  • 556
    Factors Associated with Integrase Strand Transfer Inhibitor Use between 2008- 2015
    Jane O'Halloran, MD, PhD; John Sahrmann, MA; Margaret A. Olsen, PhD, MPH; William Powderly, MD
    Efficacy and Tolerability of Integrase Inhibitors – Experiences from a Nationwide Real-life Cohort
    Botond Lakatos, MD PhD; Bernadett Lonkai, Student; János Szlávik, MD
    Immune Recovery of Acute HIV Treated Patients is Characterized by an Increase in Immune Senescence
    Rocio Jaramillo-Jante, MD; Antonio Camiro-Zúñiga, MD, MSC; Marco Najera-Avila, MD; Ayleen Cárdenas Ochoa, MCC; Christian Hernández-León, MD; Juan Luis Mosqueda-Gómez, MD; Samuel Navarro-Alarez, MD; Daniel Scott-Algara, MD, PhD; Luis E. Soto-Ramirez, MD; Brenda Crabtree-Ramirez, MD; Pablo Francisco Belaunzaran-Zamudio, MD, PHD; Juan G. Sierra-Madero, MD; Santiago Perez-Patrigeon, MD, PhD
  • Poster IDWeek2018 v3.pdf (753.0 kB)
  • CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.